Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $21.86

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given an average recommendation of “Hold” by the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $21.8571.

Several research firms recently weighed in on KROS. Wells Fargo & Company reduced their target price on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 29th. Wall Street Zen cut Keros Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. TD Cowen raised Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Finally, Zacks Research lowered Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st.

Institutional Trading of Keros Therapeutics

Large investors have recently bought and sold shares of the company. Financial Management Professionals Inc. acquired a new position in shares of Keros Therapeutics during the fourth quarter worth $29,000. Caitong International Asset Management Co. Ltd increased its stake in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after buying an additional 1,166 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after buying an additional 1,888 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in Keros Therapeutics in the 3rd quarter valued at about $47,000. Finally, SG Americas Securities LLC purchased a new position in Keros Therapeutics in the 3rd quarter valued at about $103,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $11.34 on Friday. The firm has a market capitalization of $223.60 million, a price-to-earnings ratio of 6.23 and a beta of 0.87. Keros Therapeutics has a one year low of $9.12 and a one year high of $22.55. The company’s 50 day moving average price is $16.26 and its 200 day moving average price is $16.88.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.37). Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The business had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $3.66 million. During the same quarter in the prior year, the firm earned ($1.14) earnings per share. Keros Therapeutics’s quarterly revenue was down 87.2% compared to the same quarter last year. Sell-side analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.